"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
No specific information is available on the treatment of overdosage with XIFAXAN (rifaximin) . In clinical studies at doses higher than the recommended dose ( > 600 mg/day for travelers' diarrhea or > 1100 mg/day for hepatic encephalopathy), adverse reactions were similar in subjects who received doses higher than the recommended dose and placebo. In the case of overdosage, discontinue XIFAXAN (rifaximin) , treat symptomatically, and institute supportive measures as required.
XIFAXAN (rifaximin) is contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN (rifaximin) . Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis [see ADVERSE REACTIONS].
Last reviewed on RxList: 4/19/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Xifaxan Information
Xifaxan - User Reviews
Xifaxan User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Find out what women really need.